Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
By M. Smyth, G. Dunn, Robert Schreiber. Advances in Immunology, 2006
863 citations recorded by the source corpus.
Subfields: Biotechnology, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/3dc4d20d4d1fa97bd5f9dbe93f5a4570d7bc2549
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biotechnology
In Immunology
In Oncology
Citations in the corpus
- Hallmarks of cancer: the next generation. (2011, neutral): “When cells from such nonedited tumors are serially transplanted into syngeneic recipients, the immunogenic cancer cells are rejected when they confront, for the first time, the competent immune systems of their secondary hosts (Smyth et al., 2006).”
- Breast Cancer Immunotherapy: Facts and Hopes (2017, background): “The evolving interactions between mammary tumors and host immunity are characterized by immunoediting (7).”
- Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells (2008, background): “In a rather simplified view, tumor-induced immune subversion results from two main activities, namely the induction of tolerance toward tumor antigens and the functional suppression of the effector lymphocytes that normally counteract tumor growth (1, 2, 13, 14).”
- The complexity of NF-κB signaling in inflammation and cancer (2013, background): “This anti-tumorigenic function of the immune systems with NF-κB being an important effector of it, has been designated as tumor-immunosurveillance [78].”
- Comprehensive analyses of tumor immunity: implications for cancer immunotherapy (2016, result): “We compared our results with two recent studies on the same topic [6, 11].”
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors (2011, positive): “There is strong experimental support for all three phases of cancer immuno editing, elimination, equilibrium, and escape, and many of the key cellular mediators and immune effector molecules involved in host protection from tumor development have been identified (Dunn et al., 2006; Smyth et al., 20”
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients (2008, background): “Thus, although overall survival remains the most important parameter of clinical efficacy, the adoption of new indexes that incorporate recent insights into the concept of immune equilibrium should be strongly considered (34).”
- Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation (2009, background): “In early stages of carcinogenesis, innate responses (inflammatory reactions) are indispensable for the activation of effective surveillance by adaptive immunity [77, 78] but on the other hand, are also likely to promote tumor development.”
- Dynamics of the immune reaction to pancreatic cancer from inception to invasion. (2007, background): “mised hosts suggests that cellular mechanisms of immunosurveillance influence tumor development (1, 37).”
- Toll-like receptors and cancer (2009, background): “In addition, TLRs assist natural killer (NK) cells in the killing of infected cells either by direct stimulation of TLRs on NK cells or the induction of factors such as type I interferons and IL-15 (Ref”
- Macrophages, innate immunity and cancer: balance, tolerance, and diversity. (2010, background): “In this balance progression through the three ‘E’ (elimination, equilibrium, escape) is probably mirrored by shift in this ying yang balance [71].”